#news
-
NOVITÀ
Coronavirus Pandemic: How Close Are We to a Vaccine?
Researchers around the world are racing to develop a vaccine against Covid-19, with more than 140 candidate vaccines now tracked by the World Health Organization (WHO). Vaccines normally require years of testing…
Leggi di più » -
NOVITÀ
”Blood Transfusion in Thalassaemia”: Save the Date for the Next TIF Webinar for Medical Specialists
TIF´s brand new Webinar, entitled ”Blood Transfusion in Thalassaemia” and organised as part of the eThalED Course, will be held on Monday, 31 August 2020, 15:00-16:00 EEST / 13:00-14:00 BST.…
Leggi di più » -
NOVITÀ
TIF Publishes its Annual Report for 2019
This Annual Report showcases the Federation’s intensive efforts that took place in 2019 with the aim to ensure equal access to quality healthcare for every patient with thalassaemia and haemoglobin…
Leggi di più » -
NOVITÀ
TIF.ACCESS: A Global TIF Initiative for the Promotion of the Availability & Accessibility of Innovative Therapies
The swift scientific progress made in the field of thalassaemia research has gained momentum with the market authorisations of both the Zynteglo Gene Therapy by the European Medicines Agency (EMA)…
Leggi di più » -
Clinical News
Early-Stage Trial Data on Oxford University COVID-19 Vaccine to be Published July 20
Early-stage human trial data on a vaccine being developed by Oxford University and AstraZeneca will be published on July 20, The Lancet medical journal announced yesterday. The potential vaccine is already…
Leggi di più » -
NOVITÀ
COVID-19 and Thalassaemia: A Position Statement of the Thalassaemia International Federation
Many patients with haemoglobinopathies, including thalassaemia and sickle cell disease, are at increased risk of developing severe complications from the coronavirus disease 2019 (COVID‐19). Although epidemiologic evidence concerning the novel…
Leggi di più » -
NOVITÀ
TIF Postpones its International Conference on Thalassaemia to 2021
Being mindful of the COVID-19 situation and wanting to ensure participants’ safety, TIF has taken the decision to postpone its long-awaited ’15th International Conference on Thalassaemia & other Haemoglobinopathies‘ & the ’17th TIF…
Leggi di più » -
NOVITÀ
Coronavirus Disease among Persons with Sickle Cell Disease
Individuals with sickle cell disease (SCD) are a particularly vulnerable group of patients, with a higher risk of severe complications due to COVID-19 infection than the general public. A recent…
Leggi di più » -
NOVITÀ
TIF Position Statement on the Use of DEHP Plasticisers in Medical Devices
The safety concerns linked to the use of DEHP plasticizers, a manufactured chemical common in blood bags and PVC intravenous fluid sets, has been explored – and even questioned –…
Leggi di più » -
NOVITÀ
GBT Announces Plans to Seek Regulatory Approval for Oxbryta® (Voxelotor) to Treat Sickle Cell Patients in Europe
Global Blood Therapeutics (GBT) plans to submit a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for Oxbryta (Voxelotor) be approved for treating hemolytic anemia in patients with sickle cell disease…
Leggi di più »